Biotech firm aims to streamline operations and reinvest in high-growth areas such as oncology and rare diseases as it targets ...

Moderna said mNEXSPIKE was approved by the FDA for use in all adults ages 65 and up, as well as individuals aged 12 to 64 with at least one or more underlying risk factors.

mNEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration ...

Moderna's mNEXSPIKE shows a higher vaccine efficacy as well as a similar safety profile compared to the company's original COVID-19 vaccine. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly ...

The main side effects of mNEXSPIKE were injection site pain, fatigue, headache and muscle pain, Moderna said in its press release. This story first appeared on NBCNews.com.

Moderna expects to have mNEXSPIKE available for eligible populations in the U.S. for the 2025-2026 respiratory virus season, alongside Spikevax and mRESVIA ®, the Company's approved respiratory ...

INDICATION mNEXSPIKE is a vaccine to protect against COVID-19. mNEXSPIKE is for people who have received a COVID-19 vaccine before and are: • 65 years of age and older, or ...